198 related articles for article (PubMed ID: 19626699)
21. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.
Monnerat C; Chompret A; Kannengiesser C; Avril MF; Janin N; Spatz A; Guinebretière JM; Marian C; Barrois M; Boitier F; Lenoir GM; Bressac-de Paillerets B
Fam Cancer; 2007; 6(4):453-61. PubMed ID: 17624602
[TBL] [Abstract][Full Text] [Related]
22. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
J Natl Cancer Inst; 1997 May; 89(10):697-702. PubMed ID: 9168184
[TBL] [Abstract][Full Text] [Related]
23. Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas.
Harinck F; Kluijt I; van der Stoep N; Oldenburg RA; Wagner A; Aalfs CM; Sijmons RH; Poley JW; Kuipers EJ; Fockens P; van Os TA; Bruno MJ
J Med Genet; 2012 Jun; 49(6):362-5. PubMed ID: 22636603
[TBL] [Abstract][Full Text] [Related]
24. Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers.
Gironi LC; Colombo E; Pasini B; Giorgione R; Farinelli P; Zottarelli F; Esposto E; Zavattaro E; Allara E; Ogliara P; Betti M; Dianzani I; Savoia P
Arch Dermatol Res; 2018 Dec; 310(10):769-784. PubMed ID: 30218143
[TBL] [Abstract][Full Text] [Related]
25. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
Sargen MR; Calista D; Elder DE; Massi D; Chu EY; Potrony M; Pfeiffer RM; Carrera C; Aguilera P; Alos L; Puig S; Elenitsas R; Yang XR; Tucker MA; Landi MT; Goldstein AM
J Am Acad Dermatol; 2020 Sep; 83(3):860-869. PubMed ID: 32283231
[TBL] [Abstract][Full Text] [Related]
26. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S
J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638
[TBL] [Abstract][Full Text] [Related]
27. Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population.
Lamperska K; Karezewska A; Kwiatkowska E; Mackiewicz A
Acta Biochim Pol; 2002; 49(2):369-76. PubMed ID: 12362978
[TBL] [Abstract][Full Text] [Related]
28. Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
Borroni RG; Manganoni AM; Grassi S; Grasso M; Diegoli M; Giorgianni C; Favalli V; Pavoni L; Cespa M; Arbustini E
Melanoma Res; 2017 Apr; 27(2):97-103. PubMed ID: 28060055
[TBL] [Abstract][Full Text] [Related]
29. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.
Fargnoli MC; Gandini S; Peris K; Maisonneuve P; Raimondi S
Eur J Cancer; 2010 May; 46(8):1413-20. PubMed ID: 20189796
[TBL] [Abstract][Full Text] [Related]
30. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
31. Phenocopies in melanoma-prone families with germ-line CDKN2A mutations.
Helgadottir H; Olsson H; Tucker MA; Yang XR; Höiom V; Goldstein AM
Genet Med; 2018 Sep; 20(9):1087-1090. PubMed ID: 29215650
[TBL] [Abstract][Full Text] [Related]
32. Assessing a single SNP located at TERT/CLPTM1L multi-cancer risk region as a genetic modifier for risk of pancreatic cancer and melanoma in Dutch CDKN2A mutation carriers.
Christodoulou E; Visser M; Potjer TP; van der Stoep N; Rodríguez-Girondo M; van Doorn R; Gruis N
Fam Cancer; 2019 Oct; 18(4):439-444. PubMed ID: 31203567
[TBL] [Abstract][Full Text] [Related]
33. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein.
Sun S; Pollock PM; Liu L; Karimi S; Jothy S; Milner BJ; Renwick A; Lassam NJ; Hayward NK; Hogg D; Narod SA; Foulkes WD
Int J Cancer; 1997 Nov; 73(4):531-6. PubMed ID: 9389568
[TBL] [Abstract][Full Text] [Related]
34. Genetic and environmental factors in cutaneous malignant melanoma.
Bressac-de-Paillerets B; Avril MF; Chompret A; Demenais F
Biochimie; 2002 Jan; 84(1):67-74. PubMed ID: 11900878
[TBL] [Abstract][Full Text] [Related]
35. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
[TBL] [Abstract][Full Text] [Related]
36. Geographical variation in the penetrance of CDKN2A mutations for melanoma.
Bishop DT; Demenais F; Goldstein AM; Bergman W; Bishop JN; Bressac-de Paillerets B; Chompret A; Ghiorzo P; Gruis N; Hansson J; Harland M; Hayward N; Holland EA; Mann GJ; Mantelli M; Nancarrow D; Platz A; Tucker MA;
J Natl Cancer Inst; 2002 Jun; 94(12):894-903. PubMed ID: 12072543
[TBL] [Abstract][Full Text] [Related]
37. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
[TBL] [Abstract][Full Text] [Related]
38. Multiplex melanoma families are enriched for polygenic risk.
Law MH; Aoude LG; Duffy DL; Long GV; Johansson PA; Pritchard AL; Khosrotehrani K; Mann GJ; Montgomery GW; Iles MM; Cust AE; Palmer JM; ; Shannon KF; Spillane AJ; Stretch JR; Thompson JF; Saw RPM; Scolyer RA; Martin NG; Hayward NK; MacGregor S
Hum Mol Genet; 2020 Oct; 29(17):2976-2985. PubMed ID: 32716505
[TBL] [Abstract][Full Text] [Related]
39. Variation in Cutaneous Patterns of Melanomagenesis According to Germline CDKN2A/CDK4 Status in Melanoma-Prone Families.
Sargen MR; Pfeiffer RM; Yang XR; Tucker MA; Goldstein AM
J Invest Dermatol; 2020 Jan; 140(1):174-181.e3. PubMed ID: 31326397
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.
Potrony M; Puig-Butille JA; Aguilera P; Badenas C; Tell-Marti G; Carrera C; Javier Del Pozo L; Conejo-Mir J; Malvehy J; Puig S
JAMA Dermatol; 2016 Apr; 152(4):405-12. PubMed ID: 26650189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
